|
|
 Previous Article | Table of Contents | Next Article 
Analysis of breakpoints within the bcr gene and their correlation with the
clinical course of Philadelphia-positive chronic myelogenous leukemia
M Shtalrid, M Talpaz, R Kurzrock, H Kantarjian, J Trujillo, J Gutterman, G Yoffe and M Blick
Department of Clinical Immunology and Biological Therapy, Hematology,
University of Texas M.D. Anderson Hospital and Tumor Institute, Houston
77030.
Chronic myelogenous leukemia (CML) is characterized by a reciprocal
translocation between chromosomes 9 and 22. The breakpoints on chromosome
22 are clustered within a 5.8-kilobase (kb) DNA fragment known as the
breakpoint cluster region (bcr), which encodes part of a functionally
active gene. We analyzed the bcr in DNAs from 108 consecutive, unselected
Philadelphia chromosome-positive CML patients by Southern blot and
determined five restriction enzyme fragments within which breaks occur on
chromosome 22. The exact sublocalization was determined in the DNA of 100
patients. It was found to be within the 5.8-kb in 99 patients and outside
the bcr in only one. Within the bcr, most of the breakpoints occurred in
fragments 1, 2, and 3. Overall, laboratory and clinical features of CML did
not correlate with specific breakpoint fragments, but chronic-phase
duration was longer in patients with a breakpoint in fragment 2 of the bcr.
Large 3' bcr deletions were found in nine patients but did not influence
clinical outcome. DNA from one of six patients analyzed both during chronic
phase and blastic crisis showed an additional aberrant fragment, which
suggested that a second abnormal clone developed in blastic crisis.
Volume 72,
Issue 2,
pp. 485-490,
08/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. J. P. Huntly, A. Bench, and A. R. Green
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia
Blood,
August 15, 2003;
102(4):
1160 - 1168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. P. Huntly, A. J. Bench, E. Delabesse, A. G. Reid, J. Li, M. A. Scott, L. Campbell, J. Byrne, E. Pinto, A. Brizard, et al.
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability
Blood,
May 29, 2002;
99(12):
4547 - 4553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock
The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis
Cancer Res.,
March 1, 2001;
61(6):
2343 - 2355.
[Full Text]
|
|
|
|
|
|
|
P. B. Sinclair, E. P. Nacheva, M. Leversha, N. Telford, J. Chang, A. Reid, A. Bench, K. Champion, B. Huntly, and A. R. Green
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
Blood,
February 1, 2000;
95(3):
738 - 743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Tkachuk, C. Westbrook, M Andreeff, T. Donlon, M. Cleary, K Suryanarayan, M Homge, A Redner, J Gray, and D Pinkel
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization
Science,
October 26, 1990;
250(4980):
559 - 562.
[Abstract]
[PDF]
|
|
|
|
|
